Loading...
•
Jun 30, 2021
Organogenesis Q2 2021 Earnings Report
Reported strong revenue growth and improved profitability in the second quarter of 2021.
Key Takeaways
Organogenesis Holdings Inc. reported a 79% increase in net revenue for the second quarter of 2021, reaching $123.2 million, compared to $69 million in the same period of 2020. The company also achieved a net income of $20.7 million, a significant improvement from the net loss of $5.2 million in the second quarter of 2020.
Net revenue increased by 79% year-over-year to $123.2 million.
Advanced Wound Care products revenue increased by 87% to $111.4 million.
Surgical & Sports Medicine products revenue increased by 27% to $11.8 million.
Net income reached $20.7 million, compared to a net loss of $5.2 million in the second quarter of 2020.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
The company expects net revenue of between $456 million and $472 million for the twelve months ended December 31, 2021.
Positive Outlook
- Net revenue from Advanced Wound Care products of between $423 million and $436 million.
- Net revenue from the sale of PuraPly products of between $179 million and $187 million.
- GAAP net income positive for the twelve months ended December 31, 2021.
- Adjusted EBITDA positive for the twelve months ended December 31, 2021.
Challenges Ahead
- Net revenue from Surgical & Sports Medicine products of between $33 million and $36 million, representing a decrease of approximately 18% to 24% year-over-year
Revenue & Expenses
Visualization of income flow from segment revenue to net income